Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [9]
- Comments [0]
- Validations
- Western blot [3]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MA5-13830 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- ERCC1 Monoclonal Antibody (3H11)
- Antibody type
- Monoclonal
- Antigen
- Recombinant full-length protein
- Description
- MA5-13830 targets ERCC1 in IP and WB applications and shows reactivity with Human samples.
- Antibody clone number
- 3H11
- Concentration
- 0.2 mg/mL
Submitted references Effects of taxol resistance gene 1 expression on the chemosensitivity of SGC-7901 cells to oxaliplatin.
The Concept of Divergent Targeting through the Activation and Inhibition of Receptors as a Novel Chemotherapeutic Strategy: Signaling Responses to Strong DNA-Reactive Combinatorial Mimicries.
Delayed c-Fos activation in human cells triggers XPF induction and an adaptive response to UVC-induced DNA damage and cytotoxicity.
Subcellular distribution of a fluorescence-labeled combi-molecule designed to block epidermal growth factor receptor tyrosine kinase and damage DNA with a green fluorescent species.
The ERCC1/XPF endonuclease is required for completion of homologous recombination at DNA replication forks stalled by inter-strand cross-links.
ERCC1 expression and RAD51B activity correlate with cell cycle response to platinum drug treatment not DNA repair.
Development of an unsupervised pixel-based clustering algorithm for compartmentalization of immunohistochemical expression using Automated QUantitative Analysis.
ZNRD1 might mediate UV irradiation related DNA damage and repair in human esophageal cancer cells by regulation of ERCC1.
Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.
Liu L, Bai Z, Ma X, Wang T, Yang Y, Zhang Z
Experimental and therapeutic medicine 2016 Mar;11(3):846-852
Experimental and therapeutic medicine 2016 Mar;11(3):846-852
The Concept of Divergent Targeting through the Activation and Inhibition of Receptors as a Novel Chemotherapeutic Strategy: Signaling Responses to Strong DNA-Reactive Combinatorial Mimicries.
Watt HL, Rachid Z, Jean-Claude BJ
Journal of signal transduction 2012;2012:282050
Journal of signal transduction 2012;2012:282050
Delayed c-Fos activation in human cells triggers XPF induction and an adaptive response to UVC-induced DNA damage and cytotoxicity.
Tomicic MT, Reischmann P, Rasenberger B, Meise R, Kaina B, Christmann M
Cellular and molecular life sciences : CMLS 2011 May;68(10):1785-98
Cellular and molecular life sciences : CMLS 2011 May;68(10):1785-98
Subcellular distribution of a fluorescence-labeled combi-molecule designed to block epidermal growth factor receptor tyrosine kinase and damage DNA with a green fluorescent species.
Todorova MI, Larroque AL, Dauphin-Pierre S, Fang YQ, Jean-Claude BJ
Molecular cancer therapeutics 2010 Apr;9(4):869-82
Molecular cancer therapeutics 2010 Apr;9(4):869-82
The ERCC1/XPF endonuclease is required for completion of homologous recombination at DNA replication forks stalled by inter-strand cross-links.
Al-Minawi AZ, Lee YF, Håkansson D, Johansson F, Lundin C, Saleh-Gohari N, Schultz N, Jenssen D, Bryant HE, Meuth M, Hinz JM, Helleday T
Nucleic acids research 2009 Oct;37(19):6400-13
Nucleic acids research 2009 Oct;37(19):6400-13
ERCC1 expression and RAD51B activity correlate with cell cycle response to platinum drug treatment not DNA repair.
Stordal B, Davey R
Cancer chemotherapy and pharmacology 2009 Mar;63(4):661-72
Cancer chemotherapy and pharmacology 2009 Mar;63(4):661-72
Development of an unsupervised pixel-based clustering algorithm for compartmentalization of immunohistochemical expression using Automated QUantitative Analysis.
Gustavson MD, Bourke-Martin B, Reilly DM, Cregger M, Williams C, Tedeschi G, Pinard R, Christiansen J
Applied immunohistochemistry & molecular morphology : AIMM 2009 Jul;17(4):329-37
Applied immunohistochemistry & molecular morphology : AIMM 2009 Jul;17(4):329-37
ZNRD1 might mediate UV irradiation related DNA damage and repair in human esophageal cancer cells by regulation of ERCC1.
Guo W, Zhao YP, Jiang YG, Wang RW, Hong L, Fan DM
Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus 2008;21(8):730-6
Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus 2008;21(8):730-6
Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.
Selvakumaran M, Pisarcik DA, Bao R, Yeung AT, Hamilton TC
Cancer research 2003 Mar 15;63(6):1311-6
Cancer research 2003 Mar 15;63(6):1311-6
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot of ERCC1 using ERCC1 Monoclonal Antibody (Product # MA5-13830) on A431 Cells.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis was performed on whole cell extracts (30 µg lysate) of HeLa (Lane 1), A431 (Lane 2) and KARPAS 299 (lane 3).The blots were probed with Anti-ERCC1 Mouse Monoclonal Antibody (Product # MA5-13830, 1-3 µg/mL) and detected by chemiluminescence Goat anti-Mouse IgG (H+L) Secondary Antibody, HRP conjugate (Product # 62-6520, 1:4000 dilution). A 36 kDa band corresponding to ERCC1 was observed across cell lines tested. Known quantity of protein samples were electrophoresed using Novex® NuPAGE® 12 % Bis-Tris gel (Product # NP0342BOX), XCell SureLock™ Electrophoresis System (Product # EI0002) and Novex® Sharp Pre-Stained Protein Standard (Product # LC5800). Resolved proteins were then transferred onto a nitrocellulose membrane iBlot® 2 Dry Blotting System (Product # IB21001). The membrane was probed with the relevant primary and secondary Antibody following blocking with 5 % skimmed milk. Chemiluminescent detection was performed using Pierce™ ECL Western Blotting Substrate (Product # 32106).
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Knockdown of ERCC1 was achieved by transfecting HeLa cells with ERCC1 specific siRNAs (Silencer® select Product # s4785 and s4786). Western blot analysis (Fig a) was performed using whole cell lysates from the ERCC1 knock down cells (lane 3), non-specific scrambled siRNA transfected cells (lane 2) and untransfected cells (lane 1). The blots were probed with Anti-ERCC1 Mouse Monoclonal Antibody (Product # MA5-13830, 1-3 µg/mL) and Goat anti-Mouse IgG (H+L) Secondary Antibody, HRP conjugate (Product # 62-6520, 1:4000 dilution). Densitometric analysis of this western blot is shown in histogram (Fig b). Loss of signal upon siRNA mediated knock down confirms that antibody is specific to ERCC1.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 5. TSP1 and ERCC1 are involved in Txr1-mediated L-OHP sensitivity. (A) Txr1, TSP1 and ERCC1 mRNA levels in SGC7901 cells following siCON or siTxr1 lentiviral transfection and L-OHP treatment, detected using qPCR (***P
